Computed tomography angiography

Kazakhstan Startup CerebraAI Relocates Headquarters to Silicon Valley to Address Severe Emergency Care Diagnostics Gap through Novel Generative AI Medical Imaging Approach

Retrieved on: 
Tuesday, April 2, 2024
Software, General Health, Health, Artificial Intelligence, Medical Devices, Data Management, Health Technology, Technology, Stroke, Algorithm, MRI, Magnetic resonance imaging, NCCT, Physician, Patient, Silk Road, CTA, Hospital, AI, Radiology, Computed tomography angiography, Death, Hope, Eye, Silicon, Ecosystem, Silk, Multimedia, CTP, Map, Medical imaging

View the full release here: https://www.businesswire.com/news/home/20240402257293/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240402257293/en/
    Stroke is a leading cause of death and long-term disability in the U.S. and globally.
  • Following algorithm training and extensive studies in Kazakhstan, with over 130,000 patients analyzed, development is currently underway to introduce CerebraAI’s medical imaging software to the U.S. market.
  • “CerebraAI is one of the first deep tech AI startups in Kazakhstan and they are making a meaningful difference in serving humanity with their novel approach to acute ischemic stroke detection.
  • They are pioneering a new future in emergency care medical imaging diagnostics.”

Amarin Highlights New Data Providing Potential Mechanistic Insight into Vascepa®/Vazkepa® (Icosapent Ethyl) Reduction of Cardiovascular Events

Retrieved on: 
Friday, May 12, 2023
CT, Plaque, Myocardial infarction, Diabetes, MB, Macrophage, NIRF, Triglyceride, Cardiovascular disease, Radiology, CAD, CTA, Research, Loyola University, IVUS, CH.B, Atherosclerosis, Amarin, Professional corporation, European Heart Journal: Cardiovascular Imaging, Ethyl eicosapentaenoic acid, Animal, Computed tomography angiography, Patient, European Heart Journal, Molecular imaging, American Heart, Pharmaceutical industry, Medical imaging, MD

DUBLIN, Ireland and BRIDGEWATER, N.J., May 12, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today highlighted new data describing the benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) on coronary physiology, which was published in the European Heart Journal - Cardiovascular Imaging, and plaque progression, which was presented at the American Heart Association’s Vascular Discovery 2023 meeting in Boston, MA, May 10-13.

Key Points: 
  • EVAPORATE demonstrated that in statin-treated patients, VASCEPA/VAZKEPA significantly reduced plaque burden measured by serial coronary computed tomography angiography (CTA) compared with placebo.
  • VASCEPA/VAZKEPA improved mean distal segment FFRCT at 9- and 18-months follow-up compared with placebo (P = 0.02, P = 0.03 respectively).
  • “These new findings from two different studies provide important mechanistic information about VASCEPA/VAZKEPA and further elucidate its value in reducing cardiovascular events in at-risk patients,” said Nabil Abadir, MB.
  • We are proud to add to the body of research that further demonstrates the benefit of VASCEPA/VAZKEPA."

Caristo Diagnostics Completes Series A Financing and Welcomes New CEO to Advance Ground-Breaking AI Technology for Cardiac Disease Detection

Retrieved on: 
Monday, April 17, 2023
University of Oxford, LLP, CVD, Consultant, Splenic infarction, FAI, CCTA, CCO, BGF, Medicare, Oxford Sciences Enterprises, US, Risk, Algorithm, Association of British HealthTech Industries, AI, FDA, Cardiovascular disease, Death, Computed tomography angiography, Medical device, Pharmaceutical industry, EU

OXFORD, England, April 17, 2023 /PRNewswire/ -- Caristo Diagnostics Limited, a global leader in cardiac and vascular disease diagnostics and risk prediction, today announced it has secured a further £13 million (US$16.3 million) to conclude its Series A financing round. Caristo will use the capital to advance its CaRi-Heart® technology, an AI-assisted diagnostics and risk prediction tool, into standards of cardiac care in major global markets.

Key Points: 
  • Caristo will use the capital to advance its CaRi-Heart® technology, an AI-assisted diagnostics and risk prediction tool, into standards of cardiac care in major global markets.
  • The investment was led by Oxford Science Enterprises and joined by BGF , Longwall Venture Partners , Oxford Investment Consultants LLP , Oxford University and other investors.
  • "We are thrilled that five successful institutional investors participated in the financing round which validates the vast clinical and business potential of Caristo's innovations", said Oran Muduroglu, Board Chairman of Caristo.
  • Caristo aims to change this statistic through the delivery of its state-of-the-art coronary disease diagnostic technology.

Caristo Diagnostics Completes Series A Financing and Welcomes New CEO to Advance Ground-Breaking AI Technology for Cardiac Disease Detection

Retrieved on: 
Monday, April 17, 2023
University of Oxford, LLP, CVD, Consultant, Splenic infarction, FAI, CCTA, CCO, BGF, Medicare, Oxford Sciences Enterprises, US, Risk, Algorithm, Association of British HealthTech Industries, AI, FDA, Cardiovascular disease, Death, Computed tomography angiography, Medical device, Pharmaceutical industry, EU

OXFORD, England, April 17, 2023 /PRNewswire/ -- Caristo Diagnostics Limited, a global leader in cardiac and vascular disease diagnostics and risk prediction, today announced it has secured a further £13 million (US$16.3 million) to conclude its Series A financing round. Caristo will use the capital to advance its CaRi-Heart® technology, an AI-assisted diagnostics and risk prediction tool, into standards of cardiac care in major global markets.

Key Points: 
  • Caristo will use the capital to advance its CaRi-Heart® technology, an AI-assisted diagnostics and risk prediction tool, into standards of cardiac care in major global markets.
  • The investment was led by Oxford Science Enterprises and joined by BGF , Longwall Venture Partners , Oxford Investment Consultants LLP , Oxford University and other investors.
  • "We are thrilled that five successful institutional investors participated in the financing round which validates the vast clinical and business potential of Caristo's innovations", said Oran Muduroglu, Board Chairman of Caristo.
  • Caristo aims to change this statistic through the delivery of its state-of-the-art coronary disease diagnostic technology.

Viz.ai is First to Receive FDA 510(k) Clearance for AI Algorithm for Abdominal Aortic Aneurysm

Retrieved on: 
Tuesday, March 21, 2023
Technology, Medical Devices, Health Technology, Cardiology, Software, Biotechnology, Health, General Health, Artificial Intelligence, Heart, Communication, Abdominal aortic aneurysm, Pulmonary embolism, AAA1, Food and Drug Administration, Aortic rupture, Intelligence, CTA, Multimedia, Risk, TriHealth, Viz, Death, Hospital, Triage, Rupture, AAA, MD, Patient, Physician, Blood, Korea Disease Control and Prevention Agency, Artificial intelligence, AI, FDA, Computed tomography angiography, Food, Disease, Medical device, Medical imaging

Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its algorithm intended to detect suspected abdominal aortic aneurysm (AAA).

Key Points: 
  • Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its algorithm intended to detect suspected abdominal aortic aneurysm (AAA).
  • The new artificial intelligence (AI) algorithm and clinical workflow solution will be a part of the VizTM AORTIC Module, an AI solution designed to accelerate treatment decisions for all aortic pathology.
  • An abdominal aortic aneurysm is a bulge in the abdominal aorta, the main artery that carries blood from the heart to the rest of the body.
  • Analysis of risk factors for abdominal aortic aneurysm in a cohort of more than 3 million individuals.

Methinks receives CE Marked Certification for AI-based stroke triage software

Retrieved on: 
Tuesday, February 21, 2023
AIS, LVO, Reperfusion, CE, Physician, Hospital, Stroke, Systematic review, Diagnosis, PMID, CT, CTA, Literature, National library, Acquisition, Algorithm, Patient, Intracerebral hemorrhage, US FDA, Software, Artificial intelligence, Cooper University Hospital, The lady doth protest too much, methinks, Ambient occlusion, Death, FDA, Rehabilitation, Cerebral arteries, Total permanent disability insurance, ICH, Computed tomography angiography, Innovation system, NCCT, Medicine, Medical imaging, Medical device, Pharmaceutical industry

BARCELONA, Spain, Feb. 21, 2023 /PRNewswire/ -- Methinks, a digital health Company that specializes in early detection and management of Acute Stroke (AS), using artificial intelligence (AI), today announced that it has received CE mark for its medical imaging software, Methinks Stroke Suite following a milestone year of development progress, enabling commercialization in Europe and to assist in emergency settings for the benefit of AS patients.

Key Points: 
  • Methinks Stroke Suite is the first CE marked medical device that assists in finding large vessel occlusions (LVO) both hyperdense and not.
  • Acute stroke is a serious life-threatening medical condition that affects approximately 17 million people globally each year.
  • Methinks Stroke Suite, AI-based software, is a radiological computer aided triage and notification system which uses AI algorithms to identify suspected LVO on non-contrast computed tomography (NCCT) images and computed tomography angiography (CTA).
  • Pau Rodriguez, CEO of Methinks, said: "We are delighted with the CE mark approval for our medical imaging software, Methinks Stroke Suite, which paves the way to enhance stroke patient outcomes by decreasing detection time and reducing disabilities.

Methinks receives CE Marked Certification for AI-based stroke triage software

Retrieved on: 
Tuesday, February 21, 2023
AIS, LVO, Reperfusion, CE, Physician, Hospital, Stroke, Systematic review, Diagnosis, PMID, CT, CTA, Literature, National library, Acquisition, Algorithm, Patient, Intracerebral hemorrhage, US FDA, Software, Artificial intelligence, Cooper University Hospital, The lady doth protest too much, methinks, Ambient occlusion, Death, FDA, Rehabilitation, Cerebral arteries, Total permanent disability insurance, ICH, Computed tomography angiography, Innovation system, NCCT, Medicine, Medical imaging, Medical device, Pharmaceutical industry

BARCELONA, Spain, Feb. 21, 2023 /PRNewswire/ -- Methinks, a digital health Company that specializes in early detection and management of Acute Stroke (AS), using artificial intelligence (AI), today announced that it has received CE mark for its medical imaging software, Methinks Stroke Suite following a milestone year of development progress, enabling commercialization in Europe and to assist in emergency settings for the benefit of AS patients.

Key Points: 
  • Methinks Stroke Suite is the first CE marked medical device that assists in finding large vessel occlusions (LVO) both hyperdense and not.
  • Acute stroke is a serious life-threatening medical condition that affects approximately 17 million people globally each year.
  • Methinks Stroke Suite, AI-based software, is a radiological computer aided triage and notification system which uses AI algorithms to identify suspected LVO on non-contrast computed tomography (NCCT) images and computed tomography angiography (CTA).
  • Pau Rodriguez, CEO of Methinks, said: "We are delighted with the CE mark approval for our medical imaging software, Methinks Stroke Suite, which paves the way to enhance stroke patient outcomes by decreasing detection time and reducing disabilities.

Humacyte Presents Six-Month Human Acellular Vessel™ (HAV™) Coronary Artery Bypass Graft (CABG) Data at the American Heart Association Scientific Sessions 2022 Meeting

Retrieved on: 
Monday, November 7, 2022
American Heart Association, Infection, Blood, Fresenius Medical Care, Polytetrafluoroethylene, Amputation, FDA, RCA, FACS, Annual report, Moyamoya disease, Partnership, Technology, SEC, CABG, Invention, Company, Ageing, Food, Saphenous, GLOBE, BLA, Injury, Forward-looking statement, HAV, Patient, Food and Drug Administration Amendments Act of 2007, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Coronary artery bypass surgery, Terminology, COVID-19, Intention, Regenerative medicine, HUMA, Biological engineering, Plague, AHA, Swelling, Tissue, Fast track (FDA), Patent, AV, Cell, Safety, Disease, Trauma, Nasdaq, SVG, Longevity, CT, Medicine, Computed tomography angiography, Surgeon, Vibration, Pharmaceutical industry, Medical imaging, Defense

DURHAM, N.C., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissues and advanced tissue constructs and organ systems at commercial scale, announced updated six-month results of the HAV in a baboon CABG model. These data were presented in two oral presentations at the annual American Heart Association (AHA) Scientific Sessions meeting, held in Chicago, Illinois from November 5-7, 2022.

Key Points: 
  • These data were presented in two oral presentations at the annual American Heart Association (AHA) Scientific Sessions meeting, held in Chicago, Illinois from November 5-7, 2022.
  • The data presented consisted of three baboons, aged eight to 10 years, in which the HAV was implanted as an aorta-to-right coronary artery (RCA) graft.
  • Coronary artery bypass grafting is one of the most common surgical procedures in the U.S.
  • Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications.

Worldwide Angiography Equipment Industry to 2028 - by Device, Procedure, End-users and Region - ResearchAndMarkets.com

Retrieved on: 
Monday, October 17, 2022
Radiology, Health Technology, Health, Adoption, St. Jude Medical, Growth, Abbott Laboratories, Hospital, DRAKON, Research, Guerbet, GE Healthcare, Cardiac catheterization, Fluorescein angiography, Magnetic resonance angiography, Computed tomography angiography, Philips, Digital, Boston Scientific, Medtronic, Medical imaging

The global angiography equipment market is segmented based on the device, procedure, and end-users.

Key Points: 
  • The global angiography equipment market is segmented based on the device, procedure, and end-users.
  • Based on the device, the market is segmented into angiography systems, computed tomography angiography, digital subtraction angiography, magnetic resonance angiography, catheters tube, guide wires, balloons, and others including vascular closure devices and other accessories.
  • Based on the procedure, the market is sub-segmented into coronary angiography, fluorescein angiography, microangiography, neuro-vascular angiography, and peripheral angiography.
  • Geographically the global angiography equipment market is segmented into North America, Europe, Asia Pacific, and the Rest of the World.

Outlook on the Coronary Heart Disease Diagnostic Imaging Devices Global Market to 2030 - Featuring GE Healthcare, Fujifilm, Siemens Healthineer and Toshiba Among Others - ResearchAndMarkets.com

Retrieved on: 
Tuesday, July 19, 2022
Health, Medical Devices, Cardiology, Chapter Three, CZT, Acquisition, Patient, CT scan, Hospital, CTCA, National Association Medical Staff Services, CVD, CAGR, Asia-Pacific, Moyamoya disease, Diabetes, Technology, Adoption, Computed tomography angiography, Hypertension, Myocardial perfusion imaging, Death, CHD, Medical imaging, COVID-19, Risk, Growth, Nuclear medicine, Diagnosis, PET, SPECT, Coronary artery disease, Pharmaceutical industry

For instance, intravascular ultrasound, X-ray angiography, and computed tomography angiography (CTCA) provide a direct evaluation and quantification of alterations in the coronary arteries.

Key Points: 
  • For instance, intravascular ultrasound, X-ray angiography, and computed tomography angiography (CTCA) provide a direct evaluation and quantification of alterations in the coronary arteries.
  • The coronary heart disease diagnostic imaging devices market saw a sharp decline in 2020, due to the outbreak of the COVID-19 pandemic.
  • Thus, the pandemic significantly impacted the market in 2020, which is likely to stabilize and grow exponentially by 2022.
  • Coronary Heart Disease Diagnostic Imaging Devices Market Variables, Trends & Scope